Join our daily newsletter At The Bell to receive exclusive market insights
- Invitrocue (IVQ) has completed CE Mark registration for its Onco-PDO cancer test, enabling the sale of the product in the European Economic Region
- The CE Mark requires a declaration that the product meets EU standards for health, safety and environmental protection
- Onco-PDO will soon be commercially available to oncologists and patients across Europe, starting with Germany and Spain
- Despite the good news, company shares are still locked up
- Invitrocue stock has been suspended since August 2019, last trading for six cents each
Invitrocue (IVQ) has completed CE Mark registration for its Onco-PDO cancer test, enabling the sale of the product in the European Economic Region.
Headquartered in Singapore, with operations in Australia, China, Hong Kong and Germany, the company specialises in developing cell-based testing methods to provide key insights into liver toxicology, infectious diseases and oncology.
Invitrocue’s Onco-PDO product offers an alternative to the “one-size-fits-all” approach that is common in treatments for cancer patients.
The company’s proprietary test takes a more personalised approach, enabling medical professionals to prescribe the most appropriate treatment program based on cancer cell phenotypic resistance or the patient’s response to specific chemotherapeutic drugs.
Registration for the CE Mark requires a declaration from the company that the product meets all EU standards for health, safety and environmental protection.
Dr. Andreas Lindner, CEO of Invitrocue Germany, commented on the milestone achievement.
“We are very pleased that Onco-PDO has successfully registered for the CE Mark, as Europe is a big market where we can offer our test,” Andreas explained.
“We are looking forward to helping doctors in the region make more informed decisions about the best treatment path for cancer patients,” he said.
Onco-PDO will soon be commercially available to oncologists and patients across Europe, starting in Germany and then Spain. Invitrocue also has plans to enter other markets, including Brazil.
The company will also be seeking to list the Onco-PDO test under the German Healthcare reimbursement system, although this is likely to occur later this year.
Despite the good news, company shares are still locked up.
Invitrocue stock has been suspended since August 2019, last trading for six cents each
